Dr. Gary Kaplan

Gary Kaplan D.O., DABFM, DABPM, FAAMA

  • President of the Foundation for Total Recovery
  • Founder and Medical Director of the Kaplan Center for Integrative Medicine
  • Author of Total Recovery: A Revolutionary New Approach to Breaking the Cycle of Pain and Depression (Rodale, 2014).

A Clinical Associate Professor in the Department of Community and Family Medicine at Georgetown University School of Medicine, Dr. Kaplan is one of only 19 physicians in the country to be board-certified in both Family Medicine and Pain Medicine. Also board-certified in Medical Acupuncture, he has studied and practiced Osteopathic Manipulative Medicine, Emergency Medicine, and Interventional Medicine, including Prolotherapy.

In response to growing numbers of patients presenting with heavy metal toxicity, Dr. Kaplan received certification in the science and practice of chelation therapy from The American College for Advancement in Medicine (ACAM). In 2013, Dr. Kaplan was appointed by U.S. Secretary of Health and Human Services (HHS), Kathleen Sebelius, to the Chronic Fatigue Syndrome Advisory Committee (CFSAC), where he served until 2017.

He is also the founder and medical director of the Kaplan Center for Integrative Medicine, a premier clinic that specializes in treating chronic pain and illnesses that incorporates holistic approaches, conventional and alternative medicine.

Craig Shimasaki, Ph D, MBA

Craig Shimasaki, PhD, MBA

  • CEO, Moleculera Labs, Oklahoma City
  • Adjunct Professor, University of Oklahoma

Dr. Shimasaki is co-founder and CEO of Moleculera Labs, a neuroimmunology precision medicine company focused on diagnosing neurologic, psychiatric, and behavioral disorders triggered by an autoimmune response. The company’s testing panel is based on over 20 years of work from Dr. Madeleine Cunningham’s laboratory at the University of Oklahoma Health Sciences Center.

Dr. Shimasaki has been in the biotechnology industry for over 35 years, starting his career at Genentech. As a scientist, businessperson, and serial entrepreneur his work spans all stages of research and development from bench to bedside. His R&D work included epitope mapping for an HIV vaccine, SNP-based genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutic and biologic products for infectious diseases, neuropsychiatric disorders and noise induced hearing loss. He co-founded several companies and led multiple products through the FDA approval process and is a co-inventor on several patents.

Dr. Shimasaki received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor and Senior Entrepreneur-in-Residence at the University of Oklahoma, Price School of Business and teaches biotechnology entrepreneurship.

His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.

Joseph A. Bellanti, M.D.

Joseph A. Bellanti, M.D.

Soon after arriving at Georgetown in 1963, Dr. Bellanti realized that his goal of generating new knowledge in immunology and translating it to clinical use would require adopting a multidisciplinary, translational approach to immunology that would involve a horizontal matrix including both basic and clinical investigators, allied health professionals, statisticians, and health educators and the public. Accordingly, in 1975 he established and became the Director of the International Center for Interdisciplinary Studies of Immunology at Georgetown University Medical Center and later Director of the Division of Allergy-Immunology, Department of Pediatrics and the Division of Virology and Immunology in the Department of Laboratory Medicine of Georgetown University Hospital.

Dr. Bellanti has focused a major investigative effort on antimicrobial research, evaluation of new vaccine strategies and developmental immunology. With other investigators, he has studied antibody and phagocytic cell function in the newborn human and in experimental model systems. He and his colleagues described the antiviral activity of the secretory IgA system in respiratory secretions and later cellular responses to viral infections following immunization or natural infection. Dr. Bellanti’s academic career has been nurtured by his previous research that has focused on the immunopathogenesis of infectious diseases, and the allergic and autoimmune disorders. His experience as a GUMC clinical investigator was established by a track record of successfully directing major R01, Center and Program Project awards as well as training grants. In addition to teaching medical students and residents, he directed a postgraduate training program in developmental immunology from 1968-1996 and a clinical residency program in allergy and immunology from 1978 -1992. The ICISI has trained over 300 postdoctoral candidates in basic and clinical immunology who come to the Center from the US as well as from countries throughout the world. Dr. Bellanti draws upon his pioneering experience as an established clinical investigator in the field of translational research in immunology.

Amiram Katz, MD, DABPN

Amiram Katz, MD, DABPN

Amiram Katz, a Board-Certified Neurologist, practices at MedAhead Inc. where he sees patients with protracted tick-borne diseases among other neurologically compromised patients. He was recently recognized by Marquis Who’s & Who Top Doctors for dedication, achievements, and leadership in neurology.

Dr. Katz attended the Sackler School of Medicine at Tel Aviv University, where he earned an MD in 1976 with Magna Cum Laude. He went on to complete a residency in Internal Medicine at Sheba Medical Center in 1980, a residency in Neurology at Tel Aviv Medical Center in 1984, a fellowship in medical hypnosis at the University of Haifa in 1985, a fellowship in Clinical Neurophysiology at the Cleveland Clinic in 1988 and a fellowship in Clinical Epilepsy at the Yale School of Medicine in 1989.

Dr. Katz additionally holds numerous certifications in his field, including an Israeli specialist’s Certificate in Neurology, which he earned in 1985 and American Board certification of Psychiatry and Neurology he earned in 1992. He was certified as a Diving Medical Officer in 1976 and a Medical Officer with the Israeli Academy of Military Medicine.

He is in solo practice with MedAhead, Inc., in Orange, Connecticut since 2004. Dr. Katz has been the president of this company since 1995 and has also been a consulting neurologist and Assistant Clinical Professor of Neurology at Yale University School of Medicine from 1993 to 2013. He was a partner in Neurology Associates of Norwalk PC, from 1993 to 2002. During those years he served as the Medical Director of the Epilepsy Foundation of Connecticut. From 1993 to 2002, Dr. Katz was the Director of the Epilepsy Center, Co-Director of Diving Medicine and Associate Director of Sleep Medicine – all at Norwalk Hospital. From 1996 to 1998, he served as the medical director of Telemedicine Consultants America, LLC.

In recognition of his accomplishments in his field, Dr. Katz has been the recipient of numerous awards and honors. He won the Merritt Putnam Fellowship of the American Foundation in Epilepsy in 1988, the William Gowers Epilepsy Fellowship of Abbott Pharmaceuticals in 1989 and the Hans Berger Epilepsy Fellowship of the American EEG Society in 1990. From 2002 to 2014, he was listed among the Top Doctors in the New York Metro Area with Castle Connolly, and in 2010 and 2013 he was named Most Compassionate Doctor by Patients’ Choice. In 2008, 2010, and 2012, he was awarded Best Doctor by Patients’ Choice, among myriad further accolades. In 2016 he opened a new Company, DK Electronics, LLC, to promote an FDA approved medical device he invented – FlowKeepers® – that helps prevent Deep Vein Thrombosis (DVT). In the past 5 years Dr, Katz ran an IRB approved clinical trial examining the safety and efficacy of intra thecal Immunoglobulin administration to patients with Alzheimer’s disease. A treatment that shows promise in a variety of neuroinflammatory conditions. In the coming years, he intends to experience continued growth and success with his medical device, his research and clinical trials.